PL3833343T3 - Heterocykliczne pochodne flawonu, kompozycje, i sposoby z nimi związane - Google Patents

Heterocykliczne pochodne flawonu, kompozycje, i sposoby z nimi związane

Info

Publication number
PL3833343T3
PL3833343T3 PL19847006.4T PL19847006T PL3833343T3 PL 3833343 T3 PL3833343 T3 PL 3833343T3 PL 19847006 T PL19847006 T PL 19847006T PL 3833343 T3 PL3833343 T3 PL 3833343T3
Authority
PL
Poland
Prior art keywords
compositions
methods related
flavone derivatives
heterocyclic
heterocyclic flavone
Prior art date
Application number
PL19847006.4T
Other languages
English (en)
Inventor
Keqiang Ye
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of PL3833343T3 publication Critical patent/PL3833343T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19847006.4T 2018-08-07 2019-08-07 Heterocykliczne pochodne flawonu, kompozycje, i sposoby z nimi związane PL3833343T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715764P 2018-08-07 2018-08-07
PCT/US2019/045585 WO2020033604A1 (en) 2018-08-07 2019-08-07 Heterocyclic flavone derivatives, compositions, and methods related thereto

Publications (1)

Publication Number Publication Date
PL3833343T3 true PL3833343T3 (pl) 2024-06-24

Family

ID=69415601

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19847006.4T PL3833343T3 (pl) 2018-08-07 2019-08-07 Heterocykliczne pochodne flawonu, kompozycje, i sposoby z nimi związane

Country Status (6)

Country Link
US (2) US11987589B2 (pl)
EP (2) EP3833343B1 (pl)
ES (1) ES2974972T3 (pl)
HU (1) HUE066348T2 (pl)
PL (1) PL3833343T3 (pl)
WO (1) WO2020033604A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833343B1 (en) * 2018-08-07 2024-02-21 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2023227881A1 (en) 2022-05-24 2023-11-30 Ontrack Therapeutics Limited Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
GB202207557D0 (en) * 2022-05-24 2022-07-06 Ontrack Therapeutics Ltd Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
GB202207556D0 (en) * 2022-05-24 2022-07-06 Ontrack Therapeutics Ltd Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
EP4531840A1 (en) 2022-05-24 2025-04-09 Ontrack Therapeutics Limited 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitril e for the treatment of diseases and conditions associated with movement disorders
GB2624633A (en) * 2022-11-22 2024-05-29 Ontrack Therapeutics Ltd Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
CN120916766A (zh) * 2023-02-14 2025-11-07 昂特拉克治疗有限公司 用于治疗精神分裂症的化合物
GB202302121D0 (en) * 2023-02-14 2023-03-29 Ontrack Therapeutics Ltd Compounds for use in the treatment of schizophrenia
GB2628348A (en) * 2023-03-20 2024-09-25 Ontrack Therapeutics Ltd Amelioration of drug-drug interactions
WO2025043434A1 (zh) * 2023-08-28 2025-03-06 深圳理工大学 阿尔茨海默病的预防和/或治疗药物
GB2636969A (en) * 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
GB202317991D0 (en) * 2023-11-24 2024-01-10 Ontrack Therapeutics Ltd Compounds for use in the treatment of positive symptoms in schizophrenia
WO2025109339A1 (en) * 2023-11-24 2025-05-30 Ontrack Therapeutics Limited 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitrile for use in the treatment of positive symptoms in schizophrenia
WO2025125811A1 (en) * 2023-12-12 2025-06-19 Ontrack Therapeutics Limited Heterocyclic compounds and their use for the treatment of neurological disorders
GB202318964D0 (en) * 2023-12-12 2024-01-24 Ontrack Therapeutics Ltd Novel compounds and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AU2005214167B2 (en) 2004-02-13 2008-08-07 Warner-Lambert Company Llc Androgen receptor modulators
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
MX2008016398A (es) 2006-06-21 2009-01-21 Piramal Life Sciences Ltd Compuestos enantiomericamente puros novedosos para el tratamiento de trastornos proliferativos.
CZ300589B6 (cs) 2006-09-04 2009-06-24 Univerzita Palackého Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití
US9895344B2 (en) 2008-07-25 2018-02-20 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
WO2010107866A2 (en) 2009-03-20 2010-09-23 Emory University Catecholamine derivatives for obesity and neurological disorders
CN105566272A (zh) 2010-06-09 2016-05-11 爱默蕾大学 TrkB激动剂及其用途
CN104487429B (zh) * 2012-07-27 2017-07-14 爱默蕾大学 杂环黄酮衍生物、组合物及与其相关的方法
US20160022642A1 (en) * 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
EP3833343B1 (en) * 2018-08-07 2024-02-21 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto

Also Published As

Publication number Publication date
ES2974972T3 (es) 2024-07-02
EP3833343C0 (en) 2024-02-21
EP3833343A4 (en) 2022-04-13
HUE066348T2 (hu) 2024-07-28
US20210292335A1 (en) 2021-09-23
WO2020033604A1 (en) 2020-02-13
EP3833343B1 (en) 2024-02-21
EP4344743A3 (en) 2024-06-19
US20240262840A1 (en) 2024-08-08
US11987589B2 (en) 2024-05-21
EP3833343A1 (en) 2021-06-16
EP4344743A2 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
PL3833343T3 (pl) Heterocykliczne pochodne flawonu, kompozycje, i sposoby z nimi związane
IL288104A (en) Heterocyclic compounds, preparation methods and their use
SG11202110922QA (en) Camptothecin derivatives
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
GEAP201914688A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IL267899A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
IL289197B2 (en) History of 2–hydroxycycloalkane–1–carbamoyl
IL251780B (en) Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them
IL293968B2 (en) History of furoindazole
IL283990A (en) Modified oxopyridine derivatives
PL3135110T3 (pl) Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie
ZA202106024B (en) Heterocyclic derivatives
IL290815A (en) History of alpha-d-galactopyranoside
IL279441A (en) History of N-converted tetrahydrothinopyridines and their uses
SG11202012594RA (en) Spirochromane derivatives
SG11202010985TA (en) Heterocyclic derivatives and use thereof
SI3796975T1 (sl) Derivati sulfonilaminobenzamida
PL3770162T3 (pl) Pochodne dihydrochromenu
IL247220A0 (en) Amino pyrazoline derivatives, preparations containing them and their uses
IL276125A (en) Dihydroindolizinone derivative compounds, preparations containing them and their uses
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
GB201806948D0 (en) Derivatives